Setogepram sodium salt (PBI-4050 sodium salt) is primarily investigated for its therapeutic potential in treating fibrotic diseases. It has shown promise in preclinical and clinical studies for conditions such as idiopathic pulmonary fibrosis (IPF) and diabetic nephropathy. The compound works by modulating multiple pathways involved in fibrosis, inflammation, and metabolism, making it a multi-targeted agent. Its ability to reduce fibrosis and inflammation in various tissues positions it as a potential treatment for chronic diseases characterized by excessive tissue scarring. Clinical trials have focused on its safety, tolerability, and efficacy in improving lung and kidney function in patients with these conditions. Additionally, its anti-fibrotic properties are being explored for potential applications in other organ systems affected by fibrosis, such as the liver and heart.